Dyslipidemia Clinical Trial
Official title:
Comparison Of Cardiovascular Event Rates In Elderly Patients With Newly Initiated Atorvastatin Or Simvastatin
NCT number | NCT01304641 |
Other study ID # | A2581188 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | November 2009 |
Est. completion date | February 2011 |
Verified date | February 2021 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of this study is to compare rates and risk of primary cardiovascular events among elderly patients newly initiating therapy with atorvastatin or simvastatin. The specific objectives for this project are to: 1) examine the demographic and clinical characteristics of the elderly patients in whom atorvastatin or simvastatin was newly initiated; and 2) compare cardiovascular event rates in elderly patients in whom atorvastatin or simvastatin was newly initiated.
Status | Completed |
Enrollment | 31603 |
Est. completion date | February 2011 |
Est. primary completion date | February 2011 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 65 Years and older |
Eligibility | Inclusion Criteria: - = 1 fill for atorvastatin or simvastatin (not including combination therapy) between 01 July 2006 and 30 November 2008 - Age = 65 years as of the year of index date - Continuous enrollment with medical and pharmacy benefits during the analytic period Exclusion Criteria: - 1 or more fills for a statin or other dyslipidemia medication in the 12-month pre-index period - A pharmacy fill for clopidogrel or nitrates (except concomitant hydralazine) in the 12-month pre-index period - Patients with evidence of a cardiovascular event in the 12-month pre-index period. - Patients who received both atorvastatin and simvastatin on the index date - Patients with unknown gender or region - Patients who received dyslipidemia medications other than the index drug within 1 months (30 days) following the index date |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Post-index Cardiovascular (CV) Events | CV events were defined as an inpatient or emergency department admission for heart failure (HF), myocardial infarction (MI), ischemic heart disease (IHD), cerebrovascular disease, peripheral vascular disease (PVD), aortic aneurysm, and/or revascularization. CV events were identified using medical claims. | At least 3 months from the post-index date (baseline) or end of study (28 February 2009) | |
Primary | Hazard Ratio for First Cardiovascular (CV) Event | Hazard ratio of atorvastatin versus simvastatin for first CV event. Hazard ratio of atorvastatin versus simvastatin was obtained from a Cox proportional hazards model. | At least 3 months from the post-index date (baseline) or end of study (28 February 2009) | |
Secondary | Low-density Lipoprotein Cholesterol (LDL-C) | At least 3 months from the post-index date (baseline) or end of study (28 February 2009) | ||
Secondary | Mean Dose | The first observed study medication fill during the participation identification period was defined as the index drug. The initial dose of the index drug was determined based on the pharmacy claims. | At least 3 months from the post-index date (baseline) or end of study (28 February 2009) | |
Secondary | Number of Participants Per Dose | Index dose was categorized as low dose (atorvastatin 10 mg, simvastatin up to 20 mg), medium dose (atorvastatin 20 mg, simvastatin 40 mg), and high dose (atorvastatin 40 or 80 mg, simvastatin 80 mg). | At least 3 months from the post-index date (baseline) or end of study (28 February 2009) | |
Secondary | Length of Post-index Period | Post-index period included time during which participants were observed for a minimum of 3 months following index date (fill date on which first observed atorvastatin or simvastatin was filled during the participant identification period) until disenrollment or end of study treatment (28 February 2009). | Index date (baseline) up to end of study (28 February 2009) | |
Secondary | Percentage of Participants Who Adhered to Index Therapy | Percentage of participants who adhered to index therapy was evaluated. Treatment adherence was defined as the number of days covered by index medication divided by the number of days in the post-index period, expressed as a percentage. | At least 3 months from the post-index date (baseline) or end of study (28 February 2009) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00001154 -
Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
|
||
Not yet recruiting |
NCT06405880 -
Pharmacist Case Finding and Intervention for Vascular Prevention Trial
|
N/A | |
Recruiting |
NCT02837367 -
Use of Nutrigenomic Models for the Personalized Treatment With Medical Foods in Obese People
|
N/A | |
Active, not recruiting |
NCT02223793 -
Vascular Lifestyle-Intervention and Screening in Pharmacy
|
N/A | |
Active, not recruiting |
NCT02600338 -
Meta-analyses of the Effect of Legumes on Blood Pressure
|
N/A | |
Completed |
NCT02163044 -
The Hellenic Postprandial Lipemia Study (HPLS)
|
||
Recruiting |
NCT01972113 -
Vitamin K and Glucose Metabolism in Children at Risk for Diabetes (Vita-K 'n' Kids Study)
|
N/A | |
Recruiting |
NCT01705873 -
Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen
|
N/A | |
Completed |
NCT01764295 -
Clinical Study for Patients With Hypertension Associated With Dyslipidemia
|
Phase 3 | |
Terminated |
NCT01414166 -
Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108)
|
Phase 3 | |
Completed |
NCT01990391 -
Brazil Nut Consumption in Microvascular Endothelial Function, Oxidative Stress and Metabolic Abnormalities
|
N/A | |
Completed |
NCT01531062 -
Effect of Nigella Sativa on Lipid Profiles in Elderly
|
Phase 2 | |
Recruiting |
NCT01670968 -
HIV Reverse Cholesterol Transport Study
|
||
Completed |
NCT00977288 -
A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)
|
Phase 2 | |
Completed |
NCT00768274 -
Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol
|
Phase 1/Phase 2 | |
Completed |
NCT01285544 -
The Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia
|
Phase 4 | |
Withdrawn |
NCT00664287 -
Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082)
|
Phase 3 | |
Completed |
NCT01483235 -
Reduced Cardiac Rehabilitation Program
|
N/A | |
Completed |
NCT00300430 -
Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.
|
Phase 3 | |
Completed |
NCT00143663 -
Effect of Lapaquistat Acetate on Blood Cholesterol Levels in Subjects With Elevated Cholesterol
|
Phase 3 |